日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Identification of molecularly targeted therapy-induced immunopeptidome in diffuse midline glioma (DMG)

弥漫性中线胶质瘤(DMG)中分子靶向治疗诱导的免疫肽组的鉴定

Khairkhah, Niloofar; Owolabi, Habeebah; Namvar, Ali; Ibrahim, Mostafa M H; Nyayapathy, Seeta; Jones, Richard; Rumble, Julie M; Whitehead, Christopher E; Sebolt-Leopold, Judith S; Everest-Dass, Arun; Galban, Stefanie

A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance

首创的 EGFR 和 PI3K 选择性抑制剂可通过单分子方法靶向适应性耐药

Christopher E Whitehead #, Elizabeth K Ziemke #, Christy L Frankowski-McGregor #, Rachel A Mumby, June Chung, Jinju Li, Nathaniel Osher, Oluwadara Coker, Veerabhadran Baladandayuthapani, Scott Kopetz, Judith S Sebolt-Leopold

Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence

针对弥漫性内在性脑桥胶质瘤中的 DNA 修复和存活信号来预防肿瘤复发

Monika Sharma, Ivana Barravecchia, Robert Teis, Jeanette Cruz, Rachel Mumby, Elizabeth K Ziemke, Carlos E Espinoza, Varunkumar Krishnamoorthy, Brian Magnuson, Mats Ljungman, Carl Koschmann, Joya Chandra, Christopher E Whitehead, Judith S Sebolt-Leopold, Stefanie Galban

Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition

黑色素瘤中 NF1 的缺失赋予了对 SYK 激酶抑制的敏感性

Cara Abecunas, Christopher E Whitehead, Elizabeth K Ziemke, Douglas G Baumann, Christy L Frankowski-McGregor, Judith S Sebolt-Leopold, Mohammad Fallahi-Sichani

Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition

黑色素瘤中NF1的缺失赋予其对SYK激酶抑制剂的敏感性

Cara Abecunas,Christopher E Whitehead,Elizabeth K Ziemke,Douglas G Baumann,Christy L Frankowski-McGregor,Judith S Sebolt-Leopold ,Mohammad Fallahi-Sichani

Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers

环氧合酶-2 影响胰腺癌亚群对 MEK 和 CDK4/6 共靶向的反应

Joel D Maust, Christy L Frankowski-McGregor, Armand Bankhead 3rd, Diane M Simeone, Judith S Sebolt-Leopold

Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency

靶向ADAM17可抑制人类结直肠腺癌的进展和肿瘤起始细胞频率

Dosch, Joseph; Ziemke, Elizabeth; Wan, Shanshan; Luker, Kathryn; Welling, Theodore; Hardiman, Karin; Fearon, Eric; Thomas, Suneetha; Flynn, Matthew; Rios-Doria, Jonathan; Hollingsworth, Robert; Herbst, Ronald; Hurt, Elaine; Sebolt-Leopold, Judith

Mechanistic evaluation and transcriptional signature of a glutathione S-transferase omega 1 inhibitor

谷胱甘肽 S-转移酶 omega 1 抑制剂的机制评估和转录特征

Kavya Ramkumar, Soma Samanta, Anahita Kyani, Suhui Yang, Shuzo Tamura, Elizabeth Ziemke, Jeanne A Stuckey, Si Li, Krishnapriya Chinnaswamy, Hiroyuki Otake, Bikash Debnath, Vladimir Yarovenko, Judith S Sebolt-Leopold, Mats Ljungman, Nouri Neamati

Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6

KRAS 突变型结直肠癌对 MEK 和 CDK4/6 联合治疗的敏感性

Elizabeth K Ziemke, Joseph S Dosch, Joel D Maust, Amrith Shettigar, Ananda Sen, Theodore H Welling, Karin M Hardiman, Judith S Sebolt-Leopold

Cancer stem cell marker phenotypes are reversible and functionally homogeneous in a preclinical model of pancreatic cancer

在胰腺癌的临床前模型中,癌症干细胞标志物表型是可逆的且功能上是同质的

Joseph S Dosch, Elizabeth K Ziemke, Amrith Shettigar, Alnawaz Rehemtulla, Judith S Sebolt-Leopold